FPR1 and cancer: Importantly, a previous study indicated that targeting FPR1 by ICT12035, a selective small molecule antagonist, can provide a new avenue for the therapy of cancers (31). Therefore, further investigation of FPR1 antagonists can provide opportunities for more efficient treatment of cancers, including bladder cancer.